Publication Topic

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

Menon N, Leslie TF, Frankenfeld CL. 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; doi: 10.1016/j.puhe.2020.02.004.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.

Sacks NC, Sharma A, Cyr PL, Stong L, Dahdal DN. Real-world evidence comparison of colorectal cancer screening outcomes with different colorectal cancer preparation agents in adults 65 years and older. Digestive Disease Week Annual Meeting, San Diego, May 2019.

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.